Navigation Links
Complaint Filed Regarding Proposed Merger
Date:4/22/2010

d causes of action asserted in this legal matter.

Additional Information and Where to Find It

In connection with the proposed merger, the Company has filed with the Securities and Exchange Commission (the "SEC") a Schedule 13E-3, and a preliminary proxy statement for the meeting of stockholders of the Company to be convened to approve the merger. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, THE COMPANY'S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING THE DEFINITIVE PROXY STATEMENT, WHEN IT BECOMES AVAILABLE) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. When completed a final proxy statement will be mailed to our stockholders. Investors and stockholders may obtain a free copy of the proxy statement when it becomes available, and other documents filed by us with the SEC, at the SEC's web site at http://www.sec.gov. Free copies of the proxy statement, when it becomes available, and our other filings with the SEC may also be obtained from us. Free copies of our filings may be obtained by directing a request to Dragon Pharmaceutical, Inc., 650 West Georgia Street, Suite 310, Vancouver, British Columbia, Canada V6B 4N9 Attention: Maggie Deng, Secretary.

The Company and certain of its directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be "participants" in the solicitation of proxies from our stockholders with respect to the proposed merger. Information regarding the persons who may be considered "participants" in the solici
'/>"/>

SOURCE Dragon Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
2. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
3. Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
4. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
5. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. Derma Sciences MEDIHONEY(TM) Profiled in Several Television News Health Reports
11. Mercury Therapeutics Patents Filed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/26qndf/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology by ... Nanotechnology will be applied at all stages ... optimal delivery to diagnostic applications in clinical ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... SAN CARLOS, Calif. , May 28, 2015 ... genetic testing, today announced a study published in ... that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal ... in the first trimester. A ... indicates that complete molar pregnancies occur in about ...
(Date:5/28/2015)... BRUNSWICK, N.J. , May 28, 2015 /PRNewswire/ ... PDS0101, a cancer immunotherapy treatment targeting HPV-16, has ... Currently, pre-cervical cancer is treated ... offer a simple and effective non-surgical alternative. Results ... defense mechanisms (T-cells) to recognize, target, and kill ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... Dec. 20 /PRNewswire-FirstCall/ - Athersys,Inc. (Nasdaq: ATHX ... announced today that Athersys has received authorization from ... a Phase I clinical trial,evaluating the safety of ... The companies believe that this represents the first,clinical ...
... access to ZEVALIN(R) and other novel ... ... by the House and Senate extends the 2007 reimbursement methodology,for ... had implemented new hospital outpatient reimbursement rates,for 2008 for radiopharmaceuticals ...
... abuse treatment for teens and adults, HIGHLANDS RANCH, ... the expansion of its treatment services to,include a detox ... 17 as well,as adults, and the hospital has added ... dual diagnosis (substance abuse and,mental illness)., Teen suicide ...
Cached Biology Technology:Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 2Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 3Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 4Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 5Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 6House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2
(Date:5/25/2015)... , May 25, 2015  Australia,s market for ... stage, although 2014 saw the advent of several trials ... 24 April 2015 is expected to ignite interest in ... in Australia . This in turn ... industry and drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... , A group of Japanese researchers, who publish their findings ... Biomimetics , have succeeded in building a fully functional replica ... they have filmed their model butterfly flying. Among the ... wing area is very large relative to their body mass. ...
... to minimize the use of chemical herbicides need creative solutions ... research at the University of Illinois on Canada thistle, Sudangrass ... smother crop. "Sudangrass get very tall. It outcompetes the ... occur in the thistle," said U of I weed scientist ...
... NC Social status in paper wasps is established earlier ... month in the journal PLoS ONE . While ... appearance and are fixed from birth, paper wasp society is ... can climb the social ladder and become a queen. Now, ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3The making of a queen: Road to royalty begins early in paper wasps 2
... Each vial contains 200 g of lyophilized ... sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... antigen for production of Cayman's EP1 receptor ... be used in conjunction with this antibody ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: